Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca Picks Cambridge For New Headquarters
by Alex Scott
June 24, 2013
| A version of this story appeared in
Volume 91, Issue 25
AstraZeneca will spend $515 million to build a new headquarters and global R&D hub at England’s Cambridge Biomedical Campus. The company plans to house 2,000 staffers there by 2016, including many of the 1,600 scientists now at its Alderley Park, England, labs. It plans to position small-molecule and biologics R&D activities together at the site. The campus is already host to a number of important pharmaceutical organizations. “Our people will be able to rub shoulders with some of the world’s best scientists and clinicians carrying out some of the world’s leading research,” says AstraZeneca CEO Pascal Soriot.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter